Hester Biosciences Limited (HESTERBIO.NS)
INR 2459.15
(1.23%)
INR 2459.15
(1.23%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 539.47 Million INR | -23.53% |
| 2022 | 619.2 Million INR | -5.84% |
| 2021 | 731.93 Million INR | 1.42% |
| 2020 | 700.21 Million INR | 19.85% |
| 2019 | 617.68 Million INR | -17.96% |
| 2018 | 752.45 Million INR | 47.62% |
| 2017 | 498.17 Million INR | 20.98% |
| 2016 | 414.34 Million INR | 23.3% |
| 2015 | 340.11 Million INR | 38.48% |
| 2014 | 251.84 Million INR | -0.5% |
| 2013 | 254.15 Million INR | 12.43% |
| 2012 | 219.36 Million INR | 16.22% |
| 2011 | 188.48 Million INR | 3.62% |
| 2010 | 181.89 Million INR | 12.31% |
| 2009 | 161.95 Million INR | 8.82% |
| 2008 | 148.83 Million INR | -13.71% |
| 2007 | 172.48 Million INR | 90.08% |
| 2006 | 89.11 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 176.5 Million INR | -5.94% |
| 2024 Q2 | 219.55 Million INR | 16.32% |
| 2023 Q1 | 168.79 Million INR | 11.34% |
| 2023 FY | - INR | -23.53% |
| 2023 Q4 | 159.22 Million INR | 28.89% |
| 2023 Q3 | 123.53 Million INR | -35.4% |
| 2023 Q2 | 191.22 Million INR | 13.29% |
| 2022 FY | - INR | -5.84% |
| 2022 Q1 | 121.24 Million INR | -26.31% |
| 2022 Q2 | 177.57 Million INR | 46.46% |
| 2022 Q4 | 151.6 Million INR | -39.67% |
| 2022 Q3 | 251.28 Million INR | 41.51% |
| 2021 Q4 | 164.52 Million INR | -7.61% |
| 2021 Q3 | 178.08 Million INR | -6.18% |
| 2021 Q2 | 189.82 Million INR | -2.24% |
| 2021 Q1 | 194.17 Million INR | 5.59% |
| 2021 FY | - INR | 1.42% |
| 2020 Q1 | 125.95 Million INR | 12.88% |
| 2020 Q3 | 224.49 Million INR | 39.9% |
| 2020 Q4 | 183.89 Million INR | -18.09% |
| 2020 Q2 | 160.46 Million INR | 27.4% |
| 2020 FY | - INR | 19.85% |
| 2019 Q4 | 111.57 Million INR | -46.87% |
| 2019 FY | - INR | -17.96% |
| 2019 Q1 | 181.48 Million INR | -17.98% |
| 2019 Q2 | 117.51 Million INR | -35.25% |
| 2019 Q3 | 210.01 Million INR | 78.72% |
| 2018 Q1 | 155.42 Million INR | 0.0% |
| 2018 FY | - INR | 47.62% |
| 2018 Q4 | 221.26 Million INR | 8.07% |
| 2018 Q3 | 204.74 Million INR | 29.8% |
| 2018 Q2 | 157.73 Million INR | 1.49% |
| 2017 FY | - INR | 20.98% |
| 2016 FY | - INR | 23.3% |
| 2015 FY | - INR | 38.48% |
| 2014 FY | - INR | -0.5% |
| 2013 FY | - INR | 12.43% |
| 2012 Q3 | 71.15 Million INR | 20.61% |
| 2012 Q1 | 50.99 Million INR | 0.0% |
| 2012 FY | - INR | 16.22% |
| 2012 Q4 | 37.92 Million INR | -46.7% |
| 2012 Q2 | 58.99 Million INR | 15.69% |
| 2011 FY | - INR | 3.62% |
| 2010 FY | - INR | 12.31% |
| 2009 FY | - INR | 8.82% |
| 2008 FY | - INR | -13.71% |
| 2007 FY | - INR | 90.08% |
| 2006 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Sigachi Industries Limited | 883.39 Million INR | 38.932% |
| Ind-Swift Limited | 1.06 Billion INR | 49.349% |
| Bajaj HealthCare Limited | 406.23 Million INR | -32.797% |
| Sakar Healthcare Limited | 393.26 Million INR | -37.176% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 99.127% |
| Innova Captab Limited | 1.66 Billion INR | 67.664% |
| Divi's Laboratories Limited | 25.43 Billion INR | 97.879% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 77.11% |
| Morepen Laboratories Limited | 1.72 Billion INR | 68.744% |
| Mankind Pharma Limited | 28.09 Billion INR | 98.08% |
| Sequent Scientific Limited | 549.8 Million INR | 1.879% |
| Wanbury Limited | 985.49 Million INR | 45.259% |
| Laurus Labs Limited | 8 Billion INR | 93.262% |
| Nectar Lifesciences Limited | 1.53 Billion INR | 64.869% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 92.139% |
| Alembic Limited | 1.11 Billion INR | 51.675% |
| Hikal Limited | 2.69 Billion INR | 79.962% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 94.39% |
| Neuland Laboratories Limited | 4.74 Billion INR | 88.638% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 94.221% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 95.244% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 79.304% |
| Themis Medicare Limited | 562.6 Million INR | 4.112% |
| RPG Life Sciences Limited | 1.28 Billion INR | 57.903% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 99.04% |
| Lupin Limited | 36.96 Billion INR | 98.541% |
| Amrutanjan Health Care Limited | 681.59 Million INR | 20.852% |
| Wockhardt Limited | 1.08 Billion INR | 50.049% |
| Vaishali Pharma Limited | 31.71 Million INR | -1601.208% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 86.201% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -66.781% |
| Jubilant Pharmova Limited | 8 Billion INR | 93.262% |
| FDC Limited | 3.38 Billion INR | 84.065% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.389% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -87.691% |
| Eris Lifesciences Limited | 6.98 Billion INR | 92.278% |
| Venus Remedies Limited | 711.8 Million INR | 24.211% |
| ZIM Laboratories Limited | 462.09 Million INR | -16.744% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 63.525% |
| Par Drugs and Chemicals Limited | 228.17 Million INR | -136.429% |
| Caplin Point Laboratories Limited | 6.18 Billion INR | 91.276% |
| Shilpa Medicare Limited | 2.58 Billion INR | 79.155% |
| Albert David Limited | 1.04 Billion INR | 48.397% |
| Ajanta Pharma Limited | 12.56 Billion INR | 95.707% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 88.466% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 119.117% |
| Gufic Biosciences Limited | 1.48 Billion INR | 63.561% |
| Windlas Biotech Limited | 781.72 Million INR | 30.989% |
| Procter & Gamble Health Limited | 3.07 Billion INR | 82.453% |
| Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | -1094.443% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -208.364% |
| Granules India Limited | 8.6 Billion INR | 93.73% |
| Aarti Drugs Limited | 3.24 Billion INR | 83.394% |
| Bal Pharma Limited | 345.59 Million INR | -56.1% |
| Alkem Laboratories Limited | 24.19 Billion INR | 97.77% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.61% |
| Lincoln Pharmaceuticals Limited | 1.34 Billion INR | 59.841% |
| Medicamen Biotech Limited | 245.66 Million INR | -119.6% |
| Unichem Laboratories Limited | 742.35 Million INR | 27.33% |
| Bafna Pharmaceuticals Limited | 114.58 Million INR | -370.812% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -4051.046% |
| Valiant Laboratories Limited | 12.73 Million INR | -4134.791% |
| Orchid Pharma Limited | 1.41 Billion INR | 61.987% |
| Medico Remedies Limited | 129.09 Million INR | -317.889% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 92.138% |
| Ipca Laboratories Limited | 13.29 Billion INR | 95.944% |
| Brooks Laboratories Limited | 41.72 Million INR | -1192.825% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -25.378% |
| Piramal Enterprises Limited | -3.86 Billion INR | 113.972% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 98.459% |
| NATCO Pharma Limited | 18.79 Billion INR | 97.13% |
| Suven Life Sciences Limited | -992.78 Million INR | 154.339% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 752.109% |
| Strides Pharma Science Limited | 3.76 Billion INR | 85.67% |
| Indoco Remedies Limited | 2.64 Billion INR | 79.62% |
| Alpa Laboratories Limited | 229.96 Million INR | -134.592% |
| Lasa Supergenerics Limited | -65.08 Million INR | 928.934% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 114.457% |